How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Acquired Orphan Blood Diseases Market
- By Disease Type: Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Acquired Hemophilia, Myelodysplastic Syndromes (MDS), Thrombotic Thrombocytopenic Purpura (TTP)
- By Treatment Modality: Immunosuppressive Therapy, Complement Inhibitors, Hematopoietic Stem Cell Transplantation, Blood Transfusion, Corticosteroids
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, Online Pharmacies
- By Patient Age Group: Pediatric, Adult, Geriatric
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Paroxysmal Nocturnal Hemoglobinuria (PNH) leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Acquired Orphan Blood Diseases Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disease Type 5
Treatment Modality 5
Distribution Channel 4
Patient Age Group 3
Companies profiled
Alexion Pharmaceuticals (AstraZeneca)
Sanofi
Takeda Pharmaceutical Company Limited
Grifols
S.A.
Sobi (Swedish Orphan Biovitrum)
BioMarin Pharmaceutical Inc.
Pfizer Inc.
Novartis AG
Bayer AG
Jazz Pharmaceuticals plc
Apellis Pharmaceuticals Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Alexion Pharmaceuticals (AstraZeneca)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Sanofi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Grifols
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sobi (Swedish Orphan Biovitrum)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BioMarin Pharmaceutical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Jazz Pharmaceuticals plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Apellis Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Horizon Therapeutics plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bluebird Bio Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Amgen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Roche Holding AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,494M by 2033 · 9.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Paroxysmal Nocturnal Hemoglobinuria (PNH)50.8
- Aplastic Anemia18.7
- Acquired Hemophilia6.9
- Myelodysplastic Syndromes (MDS)11.4
- Thrombotic Thrombocytopenic Purpura (TTP)12.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,212M → $2,291M · 8.3%
Europe$844.5M → $1,696M · 9.1%
Asia Pacific$771.1M → $1,626M · 9.8%
Latin America$477.3M → $1,042M · 10.3%
Middle East and Africa$367.2M → $763.1M · 9.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.292026
9.282027
9.302028
9.322029
9.322030
9.342031
9.352032
9.372033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Alexion Pharmaceuticals (AstraZeneca)20.4
- Sanofi18.7
- Takeda Pharmaceutical Company Limited7.3
- Grifols6.2
- S.A.9.4
- Sobi (Swedish Orphan Biovitrum)9.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type19.2%
Treatment Modality29.0%
Distribution Channel30.3%
Patient Age Group21.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe22.9
- Asia Pacific21.9
- Latin America14.0
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals (AstraZeneca) | 87 | 86 | 96 | 95 | 76 | 80 | 87 |
| Sanofi | 72 | 84 | 90 | 91 | 84 | 86 | 85 |
| Takeda Pharmaceutical Company Limited | 71 | 77 | 77 | 83 | 75 | 65 | 75 |
| Grifols | 73 | 68 | 62 | 74 | 68 | 58 | 67 |
| S.A. | 54 | 67 | 74 | 72 | 58 | 56 | 64 |
| Sobi (Swedish Orphan Biovitrum) | 49 | 70 | 53 | 52 | 62 | 62 | 58 |
| BioMarin Pharmaceutical Inc. | 48 | 55 | 54 | 66 | 53 | 46 | 54 |
| Pfizer Inc. | 39 | 40 | 39 | 47 | 50 | 60 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Alexion Pharmaceuticals (AstraZeneca)
- Sanofi
- Takeda Pharmaceutical Company Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals (AstraZeneca) | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Sanofi | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Takeda Pharmaceutical Company Limited | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Grifols | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| S.A. | − | ◐ | ◐ | ◐ | − | − |
| Sobi (Swedish Orphan Biovitrum) | − | ◐ | − | − | − | ◐ |
| BioMarin Pharmaceutical Inc. | ◐ | ◐ | − | ◐ | ◐ | − |
| Pfizer Inc. | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Alexion Pharmaceuticals (AstraZeneca)87
2Sanofi85
3Takeda Pharmaceutical Company Limited75
4Grifols67
5S.A.64
6Sobi (Swedish Orphan Biovitrum)58
7BioMarin Pharmaceutical Inc.54
8Pfizer Inc.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Alexion Pharmaceuticals (AstraZeneca)Sanofi
Challenger2
Strong scale, closing on the leaders.
Takeda Pharmaceutical Company LimitedGrifols
Contender2
Focused players with pockets of strength.
S.A.Sobi (Swedish Orphan Biovitrum)
Niche2
Specialists in a single segment or region.
BioMarin Pharmaceutical Inc.Pfizer Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Acquired Orphan Blood Diseases Market — a $206M beachhead inside a $3.43B market.
Beachhead (SOM)$206Mobtainable near-term
Serviceable (SAM)$1.35Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Best fit — highest urgency & budget in Disease Type.
Economic buyer77 fit
Aplastic Anemia
Strong fit — clear ROI and a fast path to value.
End user69 fit
Acquired Hemophilia
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Acquired Orphan Blood Diseases Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation14%
Closed-won7%
$8.6KCAC
$43KLTV
5.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Acquired Orphan Blood Diseases Market is a durable-growth opportunity — $9.62B by 2033, compounding at 9.1%.
TAM · 2025$4.80Btoday
TAM · 2033$9.62Bforecast
CAGR9.1%2027–2033
Cumulative$62.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.62BTotal addressable market
SAM$3.61BServiceable available market
SOM$628MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.1% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.62BLarge & growingTAM by 2033 at 9.1% CAGR
$3.61BServiceable nowreachable with today’s model
$628MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.51BBear5.9% CAGR
$9.62BBase9.1% CAGR
$12.3BBull12.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Acquired Orphan Blood Diseases Market — a $3.11B market by 2033. Plan: grow share from 6.8% to 13.9%.
Market size · 2033$3.11Btotal addressable
Market CAGR5.1%2027–2033
Target share13.9%from 6.8% today
Revenue ambition$432Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 13.9% | Ahead |
| Revenue | $231M | $432M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 36.4% | 39.9% | At risk |
| Customer retention | 87.5% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $64M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Acquired Orphan Blood Diseases Market conversation — a $7.06B market you can size, segment and defend in minutes.
Market size · 2033$7.06Btotal opportunity
Growth8.6%CAGR to 2033
Addressable buyers1,745+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Alexion Pharmaceuticals (AstraZeneca)SanofiTakeda Pharmaceutical Company LimitedGrifolsS.A.Sobi (Swedish Orphan Biovitrum)BioMarin Pharmaceutical Inc.Pfizer Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Acquired Orphan Blood Diseases Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Acquired Orphan Blood Diseases Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Acquired Von Willebrand Syndrome Market
Market size, share, segmentation and regional forecast.
$668M market · 2025 base year
View reportAcquisition Card Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportACR Impact Modifier Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportACR Impact Processing Modifier Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportAcridine Orange Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportAcrylamide Hydrogel Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportAcrylamide Monomer Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAcrylamide Oxygen Ethyl Dimethyl Methyl Acryloyl Amino Ammonium Bromide Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAcrylamide Polymers Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportAcrylamide Terpolymer Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAcrylamide Tertiary-Butyl Sulfonic Acid (ATBS) Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportAcrylate Adhesive Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.